Company Overview
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders of nervous system. The company's technology platform includes a catheter-based system incorporating microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -80.35% |
| 6 Months: | -49.75% |
| 3 Months: | -45.75% |
| 1 Month: | -54.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.95 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 82.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AMIX Autonomix Medical, Inc. PHARMA | 4.58 | -0.15 | $4.45M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | - | 0 | 0 | 0 | - | 0 | 0 | 0 |
| Operating Income | - | - | -544.00K | -871.00K | -5.82M | -2.92M | - | -2.75M | -2.84M | -2.75M | - | -3.42M | -7.53M | -3.34M |
| Net Income | -341.00K | -448.00K | -544.00K | -865.00K | -6.04M | -3.11M | -15.43M | -2.70M | -2.81M | -2.71M | -11.41M | -3.34M | -7.45M | -3.26M |
| Diluted EPS | - | - | -0.05 | - | - | -0.23 | - | - | - | - | - | - | - | - |
| R&D Expense | - | - | 199.00K | 368.00K | 471.00K | 687.00K | - | 954.00K | 1.17M | 1.04M | - | 1.59M | 2.37M | 1.72M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Operating Income | -1.99M | -12.03M | -11.59M | -17.03M |
| Net Income | -1.99M | -15.43M | -11.41M | -16.71M |
| R&D Expense | 745.00K | 2.23M | 4.72M | 7.14M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 865.00K | 9.41M | 9.81M | 7.60M |
| Total Equity | 1.96M | 644.00K | 7.63M | 8.10M | 5.89M |
| Cash & Equivalents | - | 865.00K | 8.61M | 9.14M | 7.00M |
| Total Liabilities | - | 221.00K | 1.78M | 1.71M | 1.71M |
| Current Liabilities | - | 221.00K | 777.00K | 1.71M | 1.71M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | -1.85M | -6.60M | -8.26M | -12.28M |
| Investing Cash Flow | 0 | -19.00K | -14.00K | -10.00K |
| Financing Cash Flow | 675.00K | 14.41M | 8.80M | 10.16M |
| Capital Expenditure | -0 | -19.00K | -14.00K | -10.00K |
| Free Cash Flow | -1.85M | -6.62M | -8.27M | -12.29M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | -309.0% | -202.2% | -140.9% | -283.5% |
| ROCE % | -309.0% | -139.4% | -143.1% | -289.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Mariner, LLC | 2.56% | 50.14K | $211.08K |
| 2 | Allied Private Wealth LLC | 0.02% | 347 | $1.46K |
| 3 | Tower Research Capital LLC (TRC) | 0.02% | 313 | $1.32K |
| 4 | PNC Financial Services Group, Inc. | - | 75 | $315 |
| 5 | Investors Research Corp | - | 8 | $33 |
| 6 | Networth Advisors, LLC | - | 1 | $4 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AMIX
Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026
Abstracts highlight potential of Autonomix’s transvascular technology across pain management and nervous system mapping THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Compan…
Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery
New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain THE WOODLANDS, TX, Aug. 26, 2026 (GLO…
Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules
THE WOODLANDS, TX, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered …
Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission
Final histology and laboratory analyses support the study’s safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device compa…
Autonomix Medical Receives U.S. Patent for Precision Neuromodulation Platform Expansion
Autonomix Medical (NASDAQ:AMIX) expanded its intellectual property portfolio with a new U. S.
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
Patent expands protection for technology designed to sense, map and selectively target nerves associated with tumors and cancer-related pain Strengthens Autonomix’s platform opportunity across oncology, autonomic nervous system disorders an…
AMIX — Frequently Asked Questions
What is the current share price of Autonomix Medical, Inc. (AMIX)?
As of 2026-09-19 21:16 PDT, Autonomix Medical, Inc. (AMIX) trades at $4.58 on NasdaqCM. Its 52-week range is $2.75 to $26.46.
What is the market capitalisation of AMIX?
Autonomix Medical, Inc. (AMIX) has a market capitalisation of $4.45M on NasdaqCM.
What is the P/E ratio of AMIX?
AMIX trades at a trailing price-to-earnings (P/E) ratio of -0.15. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.78.
Is AMIX a good stock to buy?
This page provides a data-driven analysis of Autonomix Medical, Inc. (AMIX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.